Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Stilgenbauer

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Blood Cancer Journal|March 12, 2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trialA Bühler, C-M Wendtner, T J Kipps, et al.
Leukemia|September 24, 2010
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutationsT Zenz, D Vollmer, M Trbusek, et al.
Leukemia|August 15, 2017
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study groupM A Hoechstetter, R Busch, B Eichhorst, et al.
Leukemia|June 28, 2017
Rare germline variants in ATM are associated with chronic lymphocytic leukemiaG Tiao, M R Improgo, S Kasar, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
The New England Journal of Medicine|August 10, 2012
Treatment of older patients with mantle-cell lymphomaH C Kluin-Nelemans, E Hoster, O Hermine, et al.
Nature Communications|February 17, 2018
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLLA Schrader, G Crispatzu, S Oberbeck, et al.
Leukemia|June 11, 2016
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaH Parker, M J J Rose-Zerilli, M Larrayoz, et al.
Blood|December 10, 2020
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signalingS Oberbeck, A Schrader, K Warner, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Blood Cancer Journal|March 12, 2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trialA Bühler, C-M Wendtner, T J Kipps, et al.
Leukemia|September 24, 2010
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutationsT Zenz, D Vollmer, M Trbusek, et al.
Leukemia|August 15, 2017
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study groupM A Hoechstetter, R Busch, B Eichhorst, et al.
Leukemia|June 28, 2017
Rare germline variants in ATM are associated with chronic lymphocytic leukemiaG Tiao, M R Improgo, S Kasar, et al.
Leukemia|June 20, 2014
Recurrent mutations refine prognosis in chronic lymphocytic leukemiaP Baliakas, A Hadzidimitriou, L-A Sutton, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
The New England Journal of Medicine|August 10, 2012
Treatment of older patients with mantle-cell lymphomaH C Kluin-Nelemans, E Hoster, O Hermine, et al.
Nature Communications|February 17, 2018
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLLA Schrader, G Crispatzu, S Oberbeck, et al.
Leukemia|June 11, 2016
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaH Parker, M J J Rose-Zerilli, M Larrayoz, et al.
Blood|December 10, 2020
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signalingS Oberbeck, A Schrader, K Warner, et al.
Pageof 10